<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Immunostimulants; Rituximab: malignant diseases; Alemtuzumab; Ofatumumab" /><meta name="IX" content="Immunostimulants; Rituximab: malignant diseases; Alemtuzumab; Ofatumumab" /><title>8.2.3 Anti-lymphocyte monoclonal antibodies: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5649-anti-lymphocyte-monoclonal-antibodies.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5590-drugs-affecting-the-immune-response.htm">8.2 Drugs affecting the immune response</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5639-tacrolimus.htm" title="Previous: TACROLIMUS">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5660-ofatumumab.htm" title="Next: OFATUMUMAB">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a301034.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Alemtuzumab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a310003.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ofatumumab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a398003.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/18904-t.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Alemtuzumab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: A &gt; Interactions of Alemtuzumab</p></div></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/24508-j.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Ofatumumab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: O &gt; Interactions of Ofatumumab</p></div></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/17534-n.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Rituximab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: R &gt; Interactions of Rituximab</p></div></li></ul><ul><li><h3>British National Formulary (7)</h3></li><li><a href="PHP5660-ofatumumab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">OFATUMUMAB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Anti-lymphocyte monoclonal antibodies</p></div></li><li><a href="PHP5661-arzerra.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Arzerra®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Anti-lymphocyte monoclonal antibodies &gt; OFATUMUMAB</p></div></li><li><a href="PHP5662-rituximab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">RITUXIMAB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Anti-lymphocyte monoclonal antibodies</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22immunostimulants%22%22rituximab%22%22alemtuzumab%22%22ofatumumab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (7)</a></li></ul><ul><li><h3>BNF for Children (5)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13856-rituximab-and-alemtuzumab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">8.2.3 Rituximab and alemtuzumab</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13858-alemtuzumab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">ALEMTUZUMAB</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Rituximab and alemtuzumab</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13859-mabcampath.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">MabCampath®</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Rituximab and alemtuzumab &gt; ALEMTUZUMAB</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22immunostimulants%22%22rituximab%22%22alemtuzumab%22%22ofatumumab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (5)</a></li></ul><ul><li><h3>Clarke's Analysis of Drugs and Poisons</h3></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/CLK1471.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; R</p></div></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/r06-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; R</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/18904-t.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Alemtuzumab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/24508-j.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ofatumumab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/17534-n.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/00228.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Alemtuzumab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; A &gt; AL</p></div></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/10461.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ofatumumab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; O &gt; OF</p></div></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/08239.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; R &gt; RI</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy (4)</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-A30.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Alemtuzumab</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; A</p></div></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-O6.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ofatumumab</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; O</p></div></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-R30.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; R</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22immunostimulants%22%22rituximab%22%22alemtuzumab%22%22ofatumumab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (4)</a></li></ul><ul><li><h3>Stockley's Drug Interactions (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E6E3E0R0D1748.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Alemtuzumab</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; A</p></div></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E2E3E0R0D931.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Rituximab</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; R</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><?highlighter on?><h1><span>8.2.3 </span>Anti-lymphocyte monoclonal antibodies</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p id="PHP5650"><strong>Rituximab</strong> causes lysis of B lymphocytes. It is licensed for the treatment of chemotherapy-resistant or relapsed stage III–IV follicular non-Hodgkin's lymphoma and, in combination with other chemotherapy, for previously untreated stage III–IV follicular lymphoma, and for previously untreated or relapsed chronic lymphocytic leukaemia (see <a title="BNF:target-block: Rituximab NICE guidance (a)" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#PHP5652">NICE guidance</a> below). Rituximab is also licensed for maintenance therapy in patients with follicular non-Hodgkin's lymphoma that has responded to induction therapy (see <a title="BNF:target-block: Rituximab NICE guidance (c)" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#PHP5653">NICE guidance</a> below). It is also licensed for use in combination with other chemotherapy for the treatment of diffuse large B-cell non-Hodgkin's lymphoma (see <a title="BNF:target-block: Rituximab NICE guidance (b)" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#PHP5654">NICE guidance</a> below). Full resuscitation facilities should be at hand and as with other cytotoxics, treatment should be undertaken under the close supervision of a specialist. See section 10.1.3 for the role of rituximab in rheumatoid arthritis.</p><p>Rituximab should be used with caution in patients receiving cardiotoxic chemotherapy or with a history of cardiovascular disease because exacerbation of angina, arrhythmia, and heart failure have been reported. Transient hypotension occurs frequently during infusion and antihypertensives may need to be withheld for 12 hours before infusion. Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.</p><p id="PHP5651">Infusion-related side-effects (including cytokine release syndrome) are reported commonly with anti-lymphocyte monoclonal antibodies and occur predominantly during the first infusion; they include fever and chills, nausea and vomiting, allergic reactions (such as rash, pruritus, angioedema, bronchospasm and dyspnoea), flushing and tumour pain. Patients should be given paracetamol and an antihistamine before each dose of anti-lymphocyte monoclonal antibodies to reduce these effects. Premedication with a corticosteroid should also be considered. The infusion may have to be stopped temporarily and the infusion-related effects treated—consult product literature for appropriate management. Evidence of pulmonary infiltration and features of tumour lysis syndrome should be sought if infusion-related effects occur. </p><p>Fatalities following <strong>severe</strong> cytokine release syndrome (characterised by severe dyspnoea) and associated with features of tumour lysis syndrome have occurred after infusions of anti-lymphocyte monoclonal antibodies. Patients with a high tumour burden as well as those with pulmonary insufficiency or infiltration are at increased risk and should be monitored <strong>very closely</strong> (and a slower rate of infusion considered).</p><div id="PHP5652" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Rituximab for the first-line treatment of stage III-IV follicular lymphoma (January 2012)</h3><p>Rituximab, in combination with:</p><ul><li><p>cyclophosphamide, vincristine and prednisolone (CVP);</p></li><li><p>cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP);</p> </li><li>  <p>mitoxantrone, chlorambucil and prednisolone (MCP);</p> </li><li>  <p>cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon-alfa (CHVPi); <em>or</em></p></li><li>  <p>chlorambucil</p></li></ul><p>is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated patients.</p><p><a href="http://www.nice.org.uk/TA243">www.nice.org.uk/TA243</a></p></div><div id="PHP5653" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (February 2008)</h3><p>Rituximab, in combination with chemotherapy, is an option for the induction of remission in patients with relapsed stage III or IV follicular non-Hodgkin's lymphoma.</p><p>Rituximab monotherapy as maintenance therapy is an option for the treatment of patients with relapsed stage III or IV follicular non-Hodgkin's lymphoma in remission induced with chemotherapy (with or without rituximab).</p><p>Rituximab monotherapy is an option for the treatment of patients with relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma, when all alternative treatment options have been exhausted (that is, if there is resistance to or intolerance of chemotherapy). </p><p><a href="http://www.nice.org.uk/TA137">www.nice.org.uk/TA137</a></p></div><div class="cI" id="PHP19210"><p class="cAE">NICE guidance</p><h3 class="cT">Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (July 2010)</h3><p>Rituximab in combination with fludarabine and cyclophosphamide is recommended as a treatment option for people with relapsed or refractory chronic lymphocytic leukaemia except when the condition:</p><ul><li>is refractory to fludarabine (that is, it has not responded to fludarabine, or has relapsed within 6 months of treatment), <strong>or</strong></li><li><p>has previously been treated with rituximab, unless it was in the context of a clinical trial, at a dose lower than the dose currently licensed for chronic lymphocytic leukaemia or with chemotherapy other than fludarabine and cyclophosphamide.</p></li></ul><p>Rituximab in combination with fludarabine and cyclophosphamide is recommended only in the context of research for patients with relapsed or refractory chronic lymphocytic leukaemia that has previously been treated with rituximab, unless rituximab has been given as specified above.</p><p><a href="http://www.nice.org.uk/TA193">www.nice.org.uk/TA193</a></p></div><div id="PHP19188" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma (June 2011)</h3><p>Rituximab maintenance therapy is recommended as an option for the treatment of people with follicular non-Hodgkins's lymphoma that has responded to first-line induction therapy with rituximab in combination with chemotherapy.</p><p><a href="http://www.nice.org.uk/TA226">www.nice.org.uk/TA226</a></p></div><div id="PHP19189" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Rituximab for the first-line treatment of chronic lymphocytic leukaemia (July 2009)</h3><p>Rituximab, in combination with fludarabine and cyclophosphamide, is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia.</p><p><a href="http://www.nice.org.uk/TA174">www.nice.org.uk/TA174</a></p></div><div id="PHP5654" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Rituximab for aggressive non-Hodgkin's lymphoma (September 2003)</h3><p>Rituximab, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone, is recommended for first-line treatment of CD20-positive diffuse large-B-cell lymphoma at clinical stage II, III or IV.</p><p>The use of rituximab for localised (stage I) disease should be limited to clinical trials.</p><p><a href="http://www.nice.org.uk/TA65">www.nice.org.uk/TA65</a></p></div><p id="PHP5655"><strong>Alemtuzumab</strong> is no longer licensed but is available through a patient access programme for oncological and transplant indications.</p><p id="PHP5657"><strong>Ofatumumab</strong> causes lysis of B lymphocytes. It is licensed for treatment of chronic lymphocytic leukaemia in patients refractory to fludarabine and alemtuzumab. Infusion-related side-effects (including cytokine release syndrome—see <a title="BNF:target-block: Anti-lymphocyte monoclonal antibodies and infusion-related side-effects" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#PHP5651">above</a>) have been reported with ofatumumab; premedication with paracetamol, an antihistamine, and a corticosteroid is recommended.</p><div class="cI" id="PHP19209"><p class="cAE">NICE guidance</p><h3 class="cT">Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (October 2010)</h3><p>Ofatumumab is <strong>not</strong> recommended for the treatment of chronic lymphocytic leukaemia that is refractory to fludarabine and alemtuzumab.</p><p>Patients currently receiving ofatumumab for this condition should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p><p><a href="http://www.nice.org.uk/TA202">www.nice.org.uk/TA202</a></p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5660-ofatumumab"><a href="PHP5660-ofatumumab.htm" title="OFATUMUMAB">OFATUMUMAB</a></li><li id="_PHP5662-rituximab"><a href="PHP5662-rituximab.htm" title="RITUXIMAB">RITUXIMAB</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5639-tacrolimus.htm">Previous: TACROLIMUS</a> | <a class="top" href="PHP5649-anti-lymphocyte-monoclonal-antibodies.htm#">Top</a> | <a accesskey="]" href="PHP5660-ofatumumab.htm">Next: OFATUMUMAB</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>